Oncotarget

Reviews:

Targeting the SET and RING-associated (SRA) domain of ubiquitin-like, PHD and ring finger–containing 1 (UHRF1) for anti-cancer drug development

Debasis Patnaik _, Pierre-Olivier Estève and Sriharsa Pradhan

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:26243-26258. https://doi.org/10.18632/oncotarget.25425

Metrics: PDF 1217 views  |   HTML 2741 views  |   ?  


Abstract

Debasis Patnaik1, Pierre-Olivier Estève2 and Sriharsa Pradhan2

1Meliorate Inc., North Weymouth, MA, 02191, USA

2New England Biolabs Inc., Ipswich, MA, 01938, USA

Correspondence to:

Debasis Patnaik, email: dpatnaik@meliorateinc.com

Sriharsa Pradhan, email: pradhan@neb.com

Keywords: UHRF1; SRA domain; cancer; DNA methylation; epigenetic target

Received: January 29, 2018     Accepted: May 02, 2018     Published: May 25, 2018

ABSTRACT

Ubiquitin-like containing PHD Ring Finger 1 (UHRF1) is a multi-domain protein with a methyl-DNA binding SRA (SET and RING-associated) domain, required for maintenance DNA methylation mediated by DNMT1. Primarily expressed in proliferating cells, UHRF1 is a cell-cycle regulated protein that is required for S phase entry. Furthermore, UHRF1 participates in transcriptional gene regulation by connecting DNA methylation to histone modifications. Upregulation of UHRF1 may serve as a biomarker for a variety of cancers; including breast, gastric, prostate, lung and colorectal carcinoma. To this end, overexpression of UHRF1 promotes cancer metastasis by triggering aberrant patterns of DNA methylation, and subsequently, silencing tumor suppressor genes. Various small molecule effectors of UHRF1 have been reported in the literature, although the mechanism of action may not be fully characterized. Small molecules that potentially bind to the SRA domain may affect the ability of UHRF1 to bind hemimethylated DNA; thereby reducing aberrant DNA methylation. Therefore, in a subset of cancers, small molecule UHRF1 inhibitors may restore normal gene expression and serve as useful anti-cancer therapeutics.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25425